Idiopátiás tüdőfibrózis: vizsgálatok itt: Izrael
6 trials · From ClinicalTrials.gov, checked 2026. november 16.. Ask the study team whether a trial fits you.
- 2. fázisTaking peopleStudy to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
- Where
- Ashdod, Ashkelon, Be’er Ya‘aqov, Hadera, Jerusalem, Kafr Saba, Petah Tikva, Ramat Gan, Rehovot, Tel Aviv
- Életkor
- 40 év and over
- People
- 324 worldwide
- Run by
- Contineum Therapeutics
See details and how to joinNCT07284459 · EU 2025-521901-42-00 - No phaseTaking peopleReal-world Study of Nerandomilast in Patients With Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis
- Where
- Ashkelon, Haifa, Ramat Gan, Tel Aviv
- Életkor
- 18 év and over
- People
- 70
- Run by
- Avraham Unterman
See details and how to joinNCT07919015 - 3. fázisNot yet taking people in IzraelLong-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
- Where
- Petah Tikva
- Életkor
- 18 év and over
- People
- 2380 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07441408 · EU 2025-522373-10-00 - 2. fázisTaking peopleA Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
- Where
- Ashkelon, Jerusalem, Kfar Saba, Petah Tikva, Rehovot
- Életkor
- 40 év and over
- People
- 359 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07652658 - 3. fázisCsak meghívásosExtension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
- Where
- Ashkelon, Hadera, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Rehovot, Tel Aviv
- Életkor
- 40 év and over
- People
- 1850 worldwide
- Run by
- United Therapeutics
See details and how to joinNCT04905693 - 3. fázisTaking peopleStudy of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
- Where
- Ashkelon, Hadera, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Rehovot, Tel Aviv
- Életkor
- 18 év and over
- People
- 698 worldwide
- Run by
- United Therapeutics
See details and how to joinNCT05943535 · EU 2023-504904-26-00